Alnylam Says Trial of Patisiran Can Continue Following Revusiran Halt
October 10 2016 - 9:20AM
Dow Jones News
Alnylam Pharmaceuticals Inc. said a phase 3 trial for one of its
drugs would continue, potentially easing investor concerns over the
safety of its portfolio.
The company said a data-monitoring committee for its Phase 3
study of the drug patisiran in patients with hereditary ATTR
amyloidosis with polyneuropathy, an inherited, progressive,
life-threatening disease that can cause sensory and motor
dysfunction resulting in disability and death, would continue.
Patients have a life expectancy of five to 15 years after the onset
of symptoms.
The company asked the committee to make its ruling after another
one of its closely watched trials was stopped last week after
patient deaths.
Last Thursday, the company's shares plummeted 46% after the
company said it would stop a late-stage trial of its drug
revusiran, a potential treatment for hereditary ATTR amyloidosis
with cardiomyopathy, after 18 patients died.
Shares rose 2.1% in light premarket trading.
"We're pleased to learn of the DMC's recommendation that dosing
can continue," Chief Medical Officer Akshay Vaishnaw said.
The company's central therapeutic approach is a method of
turning off certain genes called RNA interference, which has showed
promise in recent years.
Results of the trial are expected in mid-2017.
Write to Austen Hufford at austen.hufford@wsj.com
(END) Dow Jones Newswires
October 10, 2016 09:05 ET (13:05 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.
Alnylam Pharmaceuticals (NASDAQ:ALNY)
Historical Stock Chart
From Apr 2024 to May 2024
Alnylam Pharmaceuticals (NASDAQ:ALNY)
Historical Stock Chart
From May 2023 to May 2024